MPR Weekly Dose 84 - Emergency Use for COVID-19 treatment; Fact sheet update for vaccines; Rylaze approved; Expanded approval for Solosec; NDA submitted for HIV-1 treatment

<p><span style="font-weight: 400;">The FDA grants Emergency Use to Actemra to treat hospitalized COVID patients. R</span><span style= "font-weight: 400;">evisions are been made to the fact sheets for the Moderna and Pfizer BioNTech COVID vaccines to include information related to the risk of myocarditis and pericarditis. A new treatment is approved for some cancer patients allergic to E. coli-Derived asparaginase products. Solosec gets an expanded indication and a new drug application for a HIV-1 treatment has been submitted. </span></p>